Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Angevin

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|February 16, 2000
[Antitumor cellular immunotherapy: the breakthrough of dendritic cells]E Angevin, F André, L Zitvogel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Dendritic cell-based immunotherapy of cancerL Zitvogel, E Angevin, T Tursz
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
A hsp70-2 mutation recognized by CTL on a human renal cell carcinomaC Gaudin, F Kremer, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Exosomes for cancer immunotherapyF Andre, B Escudier, E Angevin, et al.
International Journal of Cancer|July 29, 1997
Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicityE Angevin, F Kremer, C Gaudin, et al.
Annals of Internal Medicine|May 7, 2002
Thalidomide and venous thrombosisB Escudier, N Lassau, S Leborgne, et al.
International Journal of Cancer|December 15, 1994
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administrationF Farace, E Angevin, J Vanderplancke, et al.
International Journal of Cancer|June 15, 1994
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoringF Farace, M Pallardy, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
FGFR inhibitor induced peripheral neuropathy in patients with advanced RCCY Loriot, C Massard, E Angevin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2B Escudier, F Farace, E Angevin, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|February 16, 2000
[Antitumor cellular immunotherapy: the breakthrough of dendritic cells]E Angevin, F André, L Zitvogel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Dendritic cell-based immunotherapy of cancerL Zitvogel, E Angevin, T Tursz
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
A hsp70-2 mutation recognized by CTL on a human renal cell carcinomaC Gaudin, F Kremer, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Exosomes for cancer immunotherapyF Andre, B Escudier, E Angevin, et al.
International Journal of Cancer|July 29, 1997
Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicityE Angevin, F Kremer, C Gaudin, et al.
Annals of Internal Medicine|May 7, 2002
Thalidomide and venous thrombosisB Escudier, N Lassau, S Leborgne, et al.
International Journal of Cancer|December 15, 1994
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administrationF Farace, E Angevin, J Vanderplancke, et al.
International Journal of Cancer|June 15, 1994
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoringF Farace, M Pallardy, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
FGFR inhibitor induced peripheral neuropathy in patients with advanced RCCY Loriot, C Massard, E Angevin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2B Escudier, F Farace, E Angevin, et al.
Pageof 6